

Sterling Biotech Limited May 18, 2020

Ratings

Facilities/Instruments	Amount (Rs. crore)	Rating ¹	Rating Action
Long term bank facilities	3768.00	CARE D; ISSUER NOT COOPERATING* (Single D; ISSUER NOT COOPERATING*)	Issuer not cooperating; Based on best available information
Short term bank facilities	69.68	CARE D; ISSUER NOT COOPERATING* (Single D; ISSUER NOT COOPERATING*)	Issuer not cooperating; Based on best available information
Total	3837.68 (Rs. Three Thousand Eight Hundred and Thirty Seven crore and Sixty Eight lakhs only)		

Details of instruments/facilities in Annexure-1

Detailed Rationale & Key Rating Drivers

CARE has been seeking information from Sterling Biotech Limited (SBL) to monitor the rating vide e-mail communications dated May 12, 2020, May 07, 2020, and April 30, 2020, etc. and numerous phone calls. However, despite our repeated requests, the company has not provided the requisite information for monitoring the ratings. In line with the extant SEBI guidelines, CARE has reviewed the rating on the basis of the best available information which however, in CARE's opinion is not sufficient to arrive at a fair rating. Further, SBL has not paid the surveillance fees for the rating exercise as agreed to in its Rating Agreement. The rating on SLB's bank facilities will now be denoted as **CARE D; ISSUER NOT COOPERATING***.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Detailed description of the key rating drivers Key Rating Weaknesses

Due to the weakened liquidity position there are on-going delays in servicing of interest and default in repayment of debt obligation by the company

Analytical approach: Standalone

Applicable Criteria

Policy in respect of Non-cooperation by issuer CARE's Policy on Default Recognition

About the Company

Sterling Biotech Limited (SBL), promoted by Mr. Nitin Sandesara (Managing Director), is the flagship and a listed company of the Vadodara based Sandesara group. SBL is mainly engaged in the manufacturing of pharmaceutical grade gelatin which has wide range of applications such as capsules, tablets, etc. It manufactures Di-calcium Phosphate (DCP, a by-product of gelatine) and Co-enzyme Q10 (CoQ10). DCP is mainly used by poultry feed manufacturers while CoQ10 is used as a dietary supplement used to boost human memory and immunity. SBL's manufacturing facility is located at Vadodara, Gujarat. The group has over 27 years of industrial experience and has diversified interests ranging from Pharmaceuticals, Healthcare, Oil & Gas, Engineering Infrastructure, etc. The other companies of the Sandesara group are Sterling Port Ltd, Sterling Oil Resources Ltd, Sterling SEZ & Infrastructure Ltd, PMT Machines Ltd, etc.

1 CARE Ratings Limited

²Complete definitions of the ratings assigned are available at <u>www.careratings.com</u> and in other CARE publications

^{*}Issuer did not cooperate; Based on best available information



Brief Financials (Rs. crore)	FY16 (A)	FY17 (A)
Total operating income	523.99	368.42
PBILDT	38.26	-8.38
PAT	-45.04	-41.25
Overall gearing (times)	4.10	5.72
Interest coverage (times)	0.09	-0.02

A-Audited

Status of non-cooperation with previous CRA: SBL's ratings were suspended by ICRA in July 2012 due to its inability to carry out a rating surveillance in the absence of requisite information from the company.

Any other information: NA

Rating History for last three years: Please refer Annexure-2

Annexure-1: Details of Instruments/Facilities

Name of the Instrument	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Fund-based - LT-	-	-	-	2907.62	CARE D; ISSUER NOT
Term Loan					COOPERATING*
					Issuer not cooperating; Based
					on best available information
Fund-based - LT-	-	-	-	860.38	CARE D; ISSUER NOT
Working Capital					COOPERATING*
Limits					Issuer not cooperating; Based
					on best available information
Fund-based - ST-	-	-	-	69.68	CARE D; ISSUER NOT
Others					COOPERATING*
					Issuer not cooperating; Based
					on best available information

Annexure-2: Rating History of last three years

Sr.	Name of the	Current Ratings			Rating history			
No.	Instrument/Bank	Type	Amount	Rating	Date(s) &	Date(s) &	Date(s) & Rating(s)	Date(s) &
	Facilities		Outstanding		Rating(s)	Rating(s)	assigned in 2018-	Rating(s)
			(Rs. crore)		assigned	assigned	2019	assigned in
					in 2020-	in 2019-		2017-2018
					2021	2020		
1.	Fund-based - LT-	LT	2907.62	CARE D; ISSUER	-	-	1)CARE D; ISSUER	1)CARE
	Term Loan			NOT			NOT	D
				COOPERATING*			COOPERATING*	(14-Jun-
				Issuer not			(07-Dec-18)	17)
				cooperating; Based				
				on best available				
				information				
2.	Fund-based - LT-	LT	860.38	CARE D; ISSUER	-	-	1)CARE D; ISSUER	1)CARE
	Working Capital			NOT			NOT	D
	Limits			COOPERATING*			COOPERATING*	(14-Jun-
				Issuer not			(07-Dec-18)	17)
				cooperating; Based				
				on best available				
				information				
3.	Fund-based - ST-	ST	69.68	CARE D; ISSUER	-	-	1)CARE D; ISSUER	1)CARE
	Others			NOT			NOT	D
				COOPERATING*			COOPERATING*	(14-Jun-
				Issuer not			(07-Dec-18)	17)
				cooperating; Based				
				on best available				
				information				

^{*}Issuer did not cooperate; Based on best available information

2 CARE Ratings Limited

Press Release



Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

Contact Us

Media Contact:

Name: Mradul Mishra Tel: +91-22-6837 4424

Email: mradul.mishra@careratings.com

Analyst Contact:

Name: Sharmila Jain Tel: +91-22 6754 3638

Email: sharmila.jain@careratings.com

Relationship Contact:

Ankur Sachdeva Extn +91-22 6754 495

ankur.sachdeva@careratings.com

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

3 CARE Ratings Limited